



European Society for Blood and Marrow Transplantation

# Paediatric Diseases Working Party

Chair: Peter Bader

Secretary: Andre Willasch – Co-Chair: Jean-Hughes Dalle

Statistician : Eric Behou, Study coordinator: Arnaud Dalissier, Eva Penisson


## Paediatric patients transplanted between 2000 and 2012

Table Patients		N	%
Total number of patients		37245	
Total number of transplants		43556	
Median age at diagnosis (in years)		5,16	
Median age at HSCT (in years)		7,89	
Gender	Male	22134	59.7
	Female	14921	40.3
Diagnosis	Malignant diseases	26748	
	Acute leukaemia	12756	34.3
	Chronic leukaemia	723	1.9
	Lymphoma	2492	6.7
	Plasma cell disorders	22	0.1
	Solid tumours	9013	24.2
	Myelodysplastic/Myeloproliferative	1742	4.7
	Non Malignant diseases	10469	
	Bone marrow failure	3158	8.5
	Inherited disorders	3979	10.7
	Histiocytic disorders	689	1.9
Auto-immune diseases	144	0.4	
Hemoglobinopathies	2499	6.7	


Table Centers		Malignant	%	Non malignant disease	%
Conditioning regimen	MAC	13253	94%	6780	78%
	RIC	801	6%	1861	22%
	Total	14054		8641	
Type of transplant	Allogeneic	14820	55%	10305	98%
	Autologous	11927	45%	163	2%
	Total	26747		10468	
Type of cells	BM	8094	55%	6391	64%
	PB	4741	32%	2381	24%
	CB	1753	12%	1239	12%
	Total	14660		10011	
Type of donors	Identical sibling	5361	37%	4687	46%
	Relative	1710	12%	1673	16%
	Unrelated	7577	52%	3792	37%
	Total	14648		10152	
TBI (age above 2 years old)	No	16288	69%	6757	95%
	Yes	7144	31%	319	5%
	Total	23432		7076	
Ex vivo manipulation	No	22071	90%	8607	88%
	Yes	2455	10%	1221	12%
	Total	24526		9828	

Table Outcome		Malignant	%	Non malignant disease	%
Survival	Dead	10269	39%	2031	20%
	Alive	15221	58%	7661	74%
	Lost to FU	907	3%	596	6%
	Total	26397		10288	
Relapse	No	16011	65%	8340	91%
	Yes	8609	35%	822	9%
	Total	24620		9162	
Cause of death	Relapse or progression	6356	69%	185	10%
	Secondary malignancy	60	1%	16	1%
	HSCT related	2446	27%	1540	80%
	Cell therapy	0	0%	1	0%
	Other	289	3%	174	9%
	Total	9151		1916	


## Number of HSCT in Europe / from 2000-2012



## Conditioning drugs used for these patients for malignant and non malignant diseases



## Type de cells used for identical sibling patients



## 5 years overall survival and cumulative incidence of NRM with 95% CI

